A Peek at Lineage Cell Therapeutics's Future Earnings

Lineage Cell Therapeutics (AMEX:LCTX) is set to give its latest quarterly earnings report on Tuesday, 2025-08-12. Here's what investors need to know before the announcement.

Analysts estimate that Lineage Cell Therapeutics will report an earnings per share (EPS) of $-0.02.

Lineage Cell Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.

New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).

Overview of Past Earnings

Last quarter the company beat EPS by $0.01, which was followed by a 2.55% drop in the share price the next day.

Here's a look at Lineage Cell Therapeutics's past performance and the resulting price change:

Quarter

Q1 2025

Q4 2024

Q3 2024

Q2 2024

EPS Estimate

-0.03

-0.03

-0.03

-0.04

EPS Actual

-0.02

-0.02

-0.02

-0.03

Price Change %

-3.0%

0.0%

-2.0%

3.0%

Market Performance of Lineage Cell Therapeutics's Stock

Shares of Lineage Cell Therapeutics were trading at $0.9844 as of August 08. Over the last 52-week period, shares are up 20.57%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release.

Analyst Opinions on Lineage Cell Therapeutics

For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Lineage Cell Therapeutics.

The consensus rating for Lineage Cell Therapeutics is Buy, ...